Study validating moa of intranasal foralumab in alzheimer's disease published in the prestigious journal pnas, following fda ind clearance

New york, sept. 06, 2023 (globe newswire) -- tiziana life sciences ltd. (nasdaq: tlsa) (“tiziana” or the “company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced acceptance of a publication, “nasal administration of anti-cd3 monoclonal antibody (mab) ameliorates disease in a mouse model of alzheimer's disease”, in the preeminent1 journal, proceedings of the national academy of sciences (pnas), that supports foralumab's mechanism as a potential treatment for alzheimer's disease (ad), a difficult-to-treat neuroinflammatory disease.2   this is the second publication pertaining to intranasal administration of anti-cd3 monoclonal antibody this year to be published in pnas.3
TLSA Ratings Summary
TLSA Quant Ranking